5002012025-10-012025-12-315002012025-12-315002012025-04-012025-12-315002012025-10-012025-12-31in-capmkt:OtherExpenses1Member5002012025-10-012025-12-31in-capmkt:OtherExpenses2Member5002012025-10-012025-12-31in-capmkt:OtherExpenses3Member5002012025-04-012025-12-31in-capmkt:OtherExpenses1Member5002012025-04-012025-12-31in-capmkt:OtherExpenses2Member5002012025-04-012025-12-31in-capmkt:OtherExpenses3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-04-012025-12-31in-capmkt:ReportableSegments1Member5002012025-04-012025-12-31in-capmkt:ReportableSegments2Member5002012025-04-012025-12-31in-capmkt:ReportableSegments3Member5002012025-04-012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-04-012025-12-31in-capmkt:ReportableSegments1Member5002012025-04-012025-12-31in-capmkt:ReportableSegments2Member5002012025-04-012025-12-31in-capmkt:ReportableSegments3Member5002012025-04-012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31in-capmkt:ReportableSegments1Member5002012025-12-31in-capmkt:ReportableSegments1Member5002012025-10-012025-12-31in-capmkt:ReportableSegments2Member5002012025-12-31in-capmkt:ReportableSegments2Member5002012025-10-012025-12-31in-capmkt:ReportableSegments3Member5002012025-12-31in-capmkt:ReportableSegments3Member5002012025-10-012025-12-31in-capmkt:ReportableSegments4Member5002012025-12-31in-capmkt:ReportableSegments4Member5002012025-10-012025-12-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5002012025-04-012025-12-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5002012025-12-31

Statement1

5002012025-10-012025-12-31

Statement1

5002012025-12-31

StatementDynamic1I1

Statement1

5002012025-12-31

StatementDynamic1I2

Statement1

iso4217:INRxbrli:pureiso4217:INRxbrli:shares

500201

INDIAGLYCO

NOTLISTED

INE560A01023

INDIA GLYCOLS LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2026-02-10

2026-02-03

INR

Crores

Quarterly

Third quarter

Multi segment

2026-02-10

16:00:00

2026-02-10

17:12:00

Not applicable

true

false

During the year Company has not made any default on Loans and Debt securities.

2025-10-01

2025-12-31

Unaudited

Standalone

25510600000

7400000

25518000000

5978200000

408100000

530700000

347700000

468100000

412200000

16481700000

24626700000

891300000

-8300000

883000000

129100000

101300000

230400000

652600000

-1900000

650700000

335100000

10.42

Note on Financial Results: At point no.21: 'The Board of Directors of the Company at their meeting held on 16th October, 2025 had considered and approved the raising funds through issuance of 51,03,765 Equity Shares, of face value of Rs. 5/- (Rupees Five) each, at a price of Rs. 915/- per Equity Share, (including a premium of Rs. 910/- per equity share), determined in accordance with provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for cash, for an aggregate amount of up to Rs. 4,66,99,44,975/- on preferential basis and the same has been approved by the Shareholders of the Company at their Extra Ordinary General Meeting held on 12th November, 2025. The Preferential Allotment Committee of the Board completed the allotment of the aforesaid equity shares to the respective allottee on 24th November, 2025 and the Company's paid up share capital was accordingly increased to Rs. 33,51,33,825/-. The Listing and Trading approvals from the Stock exchanges for above acquired equity shares were obtained on 5th January, 2026 effective from 6th January, 2026.' 'Face value of equity share capital' of Rs.5 is the Face value per equity share.'

2025-04-01

2025-12-31

Unaudited

Standalone

74648000000

43100000

74691100000

19277700000

1482100000

-225900000

970100000

1407700000

1141500000

48320400000

72373600000

2317500000

-8300000

2309200000

302000000

286700000

588700000

1720500000

-5600000

1714900000

335100000

27.47

Excise Duty

14487000000

Power and Fuel

1057900000

Other Expenses

936800000

Excise Duty

42315600000

Power and Fuel

3128100000

Other Expenses

2876700000

Bio-based Specialities and Performance Chemicals

3129800000

Potable Spirits

17934600000

Ennature Biopharma

503400000

Bio-Fuel

3942800000

Bio-based Specialities and Performance Chemicals

8995200000

Potable Spirits

52563400000

Ennature Biopharma

1442800000

Bio-Fuel

11646600000

25510600000

74648000000

25510600000

74648000000

Bio-based Specialities and Performance Chemicals

411300000

Potable Spirits

724300000

Ennature Biopharma

20400000

Bio-Fuel

329900000

Bio-based Specialities and Performance Chemicals

1038000000

Potable Spirits

2171500000

Ennature Biopharma

42200000

Bio-Fuel

850200000

1485900000

4101900000

468100000

1407700000

134800000

385000000

883000000

2309200000

Bio-based Specialities and Performance Chemicals

33714100000

Potable Spirits

6147400000

Ennature Biopharma

4312100000

Bio-Fuel

13478800000

57652400000

627200000

58279600000

Bio-based Specialities and Performance Chemicals

7192800000

Potable Spirits

3025500000

Ennature Biopharma

729900000

Bio-Fuel

744000000

11692200000

21801700000

33493900000

Note1: Since there is no option to fill 'Exceptional Items' in the utility, the same is clubbed with 'Unallocated corporate expenses net of unallocable income'.

Items that will not be reclassified to profit and loss

-2500000

Items that will not be reclassified to profit and loss

-7500000

-600000

-1900000

-5600000

Preferential Issues

2025-11-24

4669900000

2025-12-31

true

CARE Ratings Limited

false

No Comments

Anand Singhal

Chief Financial Officer

Noida

2026-02-10

To augment the fund requirement towards Working Capital of the Company

3502500000

During Q3FY26, the company has utilised the part of the proceeds towards repayment of working capital demand loans, cc utilisation and other short-term borrowings, towards the stated object of augmentation of funds towards working capital of the Company, Further, the object doesn't specify the usage of funds towards working capital borrowings reduction.

General Corporate Purposes

1167400000

During Q3FY26, The company has transferred the issue proceeds from the monitoring account directly into its SBI CC Account and further utilised the funds of Rs. 116.74 crore towards repayment of instalments for Term Loans during Q3FY26.